The stock's rise snapped a four-day losing streak.

This was the stock's second consecutive day of losses.

March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a d NORWOOD, Mass., Feb. 25 ...

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...

As of February 19, 2025, the average one-year price target for Corbus Pharmaceuticals Holdings is $57.91/share. The forecasts range from a low of $35.35 to a high of $78.75.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) have earned an average recommendation of “Buy” from the nine analysts that are currently covering the firm ...

H.C. Wainwright lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $50 from $75 and keeps a Buy rating on the shares. The firm ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...